VHCP Management III, LLC
Reporting owner on Forms 3, 4 and 5, CIK 1738053.
- Also a 13F filer: VHCP Management III, LLC
- In the filer group Venrock Healthcare Capital Partners III, L.P.
VHCP Management III, LLC reported on 1 issuer in 10 filings, the latest a Form 4 filed 2026-11-04.
Issuers
| Issuer | Roles in the latest filing | Filings | Last filed |
|---|---|---|---|
| Lycia Therapeutics, Inc. CIK 1806540 | 10% owner | 4 | 2026-11-04 |
Transactions and holdings
Every row of the person's Forms 3, 4 and 5, newest first, with the price and the amount owned after the row as filed.
| Security | Date | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| Lycia Therapeutics, Inc. Common Stock | 2026-11-02 | P bought | +8,305 | $26.95 | 6,858,542 | Form 4 |
| Lycia Therapeutics, Inc. Common Stock | 2026-10-30 | P bought | +8,804 | $26.27 | 6,850,037 | Form 4 |
| Lycia Therapeutics, Inc. Common Stock | 2026-10-30 | P bought | +200 | $26.86 | 6,850,237 | Form 4 |
| Lycia Therapeutics, Inc. Common Stock | 2026-10-29 | P bought | +1,000 | $26.33 | 6,841,233 | Form 4 |
| Lycia Therapeutics, Inc. Common Stock | 2026-10-28 | P bought | +10,570 | $25.23 | 6,835,803 | Form 4 |
| Lycia Therapeutics, Inc. Common Stock | 2026-10-28 | P bought | +4,430 | $25.97 | 6,840,233 | Form 4 |
| Lycia Therapeutics, Inc. Common Stock | 2026-10-27 | P bought | +8,729 | $25.84 | 6,794,166 | Form 4 |
| Lycia Therapeutics, Inc. Common Stock | 2026-10-27 | P bought | +31,067 | $26.84 | 6,825,233 | Form 4 |
| Lycia Therapeutics, Inc. Common Stock | 2026-10-26 | C converted | +4,779,793 | 4,832,732 | Form 4 | |
| Lycia Therapeutics, Inc. Common Stock | 2026-10-26 | P bought | +1,944,444 | $18 | 6,777,176 | Form 4 |
| Lycia Therapeutics, Inc. Common Stock | 2026-10-26 | P bought | +8,261 | $26.97 | 6,785,437 | Form 4 |
| Lycia Therapeutics, Inc. Series C Preferred Stock, derivative | 2026-10-26 | C converted | -17,142,578 | $0 | 0 | Form 4 |
| Lycia Therapeutics, Inc. Series D Preferred Stock, derivative | 2026-10-26 | C converted | -4,408,091 | $0 | 0 | Form 4 |
| Lycia Therapeutics, Inc. Common Stock | 2026-10-23 | P bought | +24,560 | $25.68 | 24,560 | Form 4 |
| Lycia Therapeutics, Inc. Common Stock | 2026-10-23 | P bought | +28,379 | $26.11 | 52,939 | Form 4 |
| Lycia Therapeutics, Inc. Series C Preferred Stock, derivative, holding | Form 3 | |||||
| Lycia Therapeutics, Inc. Series D Preferred Stock, derivative, holding | Form 3 |
Filings
The person's Forms 3, 4 and 5, and any 13D or 13G naming it.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| Form 4 0001231919-26-001536 | Lycia Therapeutics, Inc. | 2026-11-04 | ||
| Form 4 0001231919-26-001519 | Lycia Therapeutics, Inc. | 2026-10-30 | ||
| Form 4 0001231919-26-001503 | Lycia Therapeutics, Inc. | 2026-10-27 | ||
| Form 3 0001231919-26-001493 | Lycia Therapeutics, Inc. | 2026-10-22 | ||
| 13F-HR 0000950123-20-001882 | Quarter ended 2019-12-31 | 2020-02-13 | acceptance time not in the bulk data set | |
| 13F-HR 0000950123-19-010838 | Quarter ended 2019-09-30 | 2019-11-13 | acceptance time not in the bulk data set | |
| 13F-HR 0000950123-19-007812 | Quarter ended 2019-06-30 | 2019-08-13 | acceptance time not in the bulk data set | |
| 13F-HR 0000950123-19-004908 | Quarter ended 2019-03-31 | 2019-05-14 | acceptance time not in the bulk data set | |
| 13F-HR 0000950123-19-001655 | Quarter ended 2018-12-31 | 2019-02-13 | acceptance time not in the bulk data set | |
| 13F-HR 0000950123-18-011333 | Quarter ended 2018-09-30 | 2018-11-13 | acceptance time not in the bulk data set |